SAPPHIRE Held Up To The Light: Surgeons Reflect On Carotid Stent Data
This article was originally published in The Gray Sheet
Executive Summary
FDA panelist Anthony Comerota, MD, is challenging carotid stent proponents to prove the technology's superiority over endarterectomy in a more relevant patient group than Johnson & Johnson/Cordis' SAPPHIRE trial enrolled
You may also be interested in...
Carotid Stenting Stroke Is Not Caused Solely By Emboli – VEITH Panelist
Hemodynamic events, in addition to embolic obstructions, are responsible for injuries to the brain associated with carotid artery stenting, according to Sumaira Macdonald, PhD, Freeman Hospital, Newcastle-on-Tyne, UK
Carotid Stenting Stroke Is Not Caused Solely By Emboli – VEITH Panelist
Hemodynamic events, in addition to embolic obstructions, are responsible for injuries to the brain associated with carotid artery stenting, according to Sumaira Macdonald, PhD, Freeman Hospital, Newcastle-on-Tyne, UK
Asymptomatic Carotid Stenting Evaluated By Abbott’s ACT-I Study
Abbott's ACT-I trial is the first randomized clinical trial comparing carotid stenting to endarterectomy surgery in asymptomatic, surgery-eligible patients